Prime Medicine Inc (PRME) Stock Price, Quote & News

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and peg...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 465 0013

Website: primemedicine.com

Address:

60 First Street, Cambridge, United States

Blankbeanie Jul. 19 at 4:28 PM

$PRME apparently voting yes will drop the price from here on. Any thoughts?

1 · Reply

StocksNCash Jul. 19 at 3:57 PM

Looking for some positive moves next week: $CRBU $PRME $VIR $HIVE $IGC

0 · Reply

X_Master1980 Jul. 19 at 9:57 AM

$PRME I TOLD YOU 👎🏻👎🏻

1 · Reply

mcnulty2002 Jul. 18 at 9:11 PM

$CRSP Congrats CRISPR fam! Check out $PRME and $NTLA! We can all win together!

2 · Reply

mcnulty2002 Jul. 18 at 7:59 PM

$PRME Solid Day

0 · Reply

OnTheBalance Jul. 18 at 7:58 PM

$PRME pretty telling ..watch volume bars

2 · Reply

mcnulty2002 Jul. 18 at 5:36 PM

$PRME That $CRSP insider is huge for all gene editing stocks. The cool thing is a lot of these companies can win together so when one does well everyone will get more attention!

0 · Reply

Wax_Bean_futures Jul. 18 at 5:36 PM

$PRME So happy for the recent pullback (finally). Lowest share price I got was $3.88. How about all of you?

2 · Reply

OnTheBalance Jul. 18 at 2:36 PM

$PRME Expect the asymmetric reward-risk move up on Prime to be much bigger than in its counterparts

1 · Reply

LotOfAction Jul. 18 at 2:12 PM

$PRME $NTLA Something big is coming…

2 · Reply

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Jul 16, 2025, 7:00 AM EDT - 3 days ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Jul 7, 2025, 4:45 PM EDT - 12 days ago

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

May 29, 2025, 8:00 AM EDT - 7 weeks ago

Prime Medicine to Participate in Upcoming Investor Conferences

May 19, 2025, 8:31 AM EDT - 2 months ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:30 AM EDT - 2 months ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 8, 2025, 8:00 AM EDT - 2 months ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Mar 18, 2025, 7:00 AM EDT - 4 months ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Feb 28, 2025, 8:00 AM EST - 5 months ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 8:00 AM EST - 5 months ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 12:26 PM EST - 6 months ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Nov 26, 2024, 5:10 AM EST - 8 months ago

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

BMY

Nov 21, 2024, 4:18 AM EST - 8 months ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Oct 24, 2024, 8:00 AM EDT - 9 months ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 15, 2024, 8:00 AM EDT - 9 months ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Sep 30, 2024, 12:17 PM EDT - 10 months ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 8:38 AM EDT - 10 months ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Sep 30, 2024, 7:01 AM EDT - 10 months ago

Prime Medicine Unveils Strategically Focused Pipeline

May 13, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 12, 2024, 3:00 AM EDT - 1 year ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

May 10, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Mar 1, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 4:01 PM EST - 1 year ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 14, 2024, 11:50 PM EST - 1 year ago

Prime Medicine Announces Pricing of Upsized Public Offering

Feb 14, 2024, 4:05 PM EST - 1 year ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Jan 28, 2024, 8:11 AM EST - 1 year ago

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Jan 25, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Jan 25, 2024, 8:00 AM EST - 1 year ago

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Jan 5, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Jan 2, 2024, 8:00 AM EST - 1 year ago

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 2:45 PM EST - 1 year ago

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

CRSP

Nov 8, 2023, 8:00 AM EST - 1 year ago

Prime Medicine to Present at Upcoming Investor Conferences

Nov 3, 2023, 4:01 PM EDT - 1 year ago

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Oct 27, 2023, 6:00 AM EDT - 1 year ago

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

Oct 24, 2023, 7:30 AM EDT - 1 year ago

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

Sep 27, 2023, 8:49 AM EDT - 1 year ago

Prime Medicine: Not Yet Primed For Retail Investment

Aug 7, 2023, 4:01 PM EDT - 2 years ago

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jun 22, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

May 31, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine to Present at Investor Conferences in June

May 17, 2023, 4:05 PM EDT - 2 years ago

Prime Medicine to Present at Virtual Investor Conferences in May

May 17, 2023, 6:00 AM EDT - 2 years ago

Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting

May 11, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates

Apr 23, 2023, 9:10 AM EDT - 2 years ago

Prime Medicine: Gene Editing Tech With Unique Approach

Mar 27, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days

Mar 9, 2023, 8:00 AM EST - 2 years ago

Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 27, 2023, 8:00 AM EST - 2 years ago

Prime Medicine to Present at Cowen 43rd Annual Health Care Conference

Blankbeanie Jul. 19 at 4:28 PM

$PRME apparently voting yes will drop the price from here on. Any thoughts?

1 · Reply

StocksNCash Jul. 19 at 3:57 PM

Looking for some positive moves next week: $CRBU $PRME $VIR $HIVE $IGC

0 · Reply

X_Master1980 Jul. 19 at 9:57 AM

$PRME I TOLD YOU 👎🏻👎🏻

1 · Reply

mcnulty2002 Jul. 18 at 9:11 PM

$CRSP Congrats CRISPR fam! Check out $PRME and $NTLA! We can all win together!

2 · Reply

mcnulty2002 Jul. 18 at 7:59 PM

$PRME Solid Day

0 · Reply

OnTheBalance Jul. 18 at 7:58 PM

$PRME pretty telling ..watch volume bars

2 · Reply

mcnulty2002 Jul. 18 at 5:36 PM

$PRME That $CRSP insider is huge for all gene editing stocks. The cool thing is a lot of these companies can win together so when one does well everyone will get more attention!

0 · Reply

Wax_Bean_futures Jul. 18 at 5:36 PM

$PRME So happy for the recent pullback (finally). Lowest share price I got was $3.88. How about all of you?

2 · Reply

OnTheBalance Jul. 18 at 2:36 PM

$PRME Expect the asymmetric reward-risk move up on Prime to be much bigger than in its counterparts

1 · Reply

LotOfAction Jul. 18 at 2:12 PM

$PRME $NTLA Something big is coming…

2 · Reply

OnTheBalance Jul. 18 at 2:05 PM

$PRME Notice the loser post below relying on dumb giffys.. small account getting smaller 😂

0 · Reply

Totaie Jul. 18 at 1:35 PM

$PRME ik numbers are hard m8 but this says 4

0 · Reply

MKRReformed Jul. 18 at 1:33 PM

$PRME yup

0 · Reply

X_Master1980 Jul. 18 at 11:59 AM

$PRME I Told You

1 · Reply

jeojackson Jul. 18 at 8:42 AM

$PRME Been buying on the objective that 4 will be a short term bottom.

0 · Reply

RocroBio Jul. 18 at 6:34 AM

$PRME …

0 · Reply

RocroBio Jul. 18 at 6:20 AM

$PRME

0 · Reply

ONLYBULLS123 Jul. 18 at 2:57 AM

$PRME Insider https://x.com/middlemanworld/status/1943098000055718110?s=12

0 · Reply

LotOfAction Jul. 17 at 9:50 PM

$PRME good interview with CEO discussing Wilson’s disease, alpha-one antitrypsin and cystic fibrosis https://x.com/biotechtv/status/1945911638625853830?s=46&t=E2a-_N7n0SQJJyi6HV4MBQ

1 · Reply

mcnulty2002 Jul. 17 at 8:38 PM

$PRME A day old but not sure I saw it posted here. Apologies if it has been https://news.ubisoft.com/en-us/article/4tiTYS8oDJ3ygEoJHIyrdQ/netflix-greenlights-assassins-creed-liveaction-series

1 · Reply

RocroBio Jul. 17 at 6:40 PM

$PRME she’s ready

0 · Reply

OnTheBalance Jul. 17 at 5:49 PM

$PRME algo running its usual "bore and frustrate them" mode ..until its NOT :)))

2 · Reply

Market Cap	555.47M
Revenue (ttm)	2.98M
Net Income (ttm)	-195.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,573.15%
Debt to Equity Ratio	0.00

Volume	6,281,200
Avg Vol	3,850,916
Day's Range	N/A - N/A
Shares Out	134.50M
Stochastic %K	33%
Beta	2.33
Analysts	Strong Sell
Price Target	$8.28